Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

USA - NASDAQ:LXEO - US52886X1072 - Common Stock

8.2 USD
+0.17 (+2.12%)
Last: 10/9/2025, 7:26:17 PM
8.15 USD
-0.05 (-0.61%)
After Hours: 10/9/2025, 7:26:17 PM
Fundamental Rating

2

Overall LXEO gets a fundamental rating of 2 out of 10. We evaluated LXEO against 536 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXEO has reported negative net income.
In the past year LXEO has reported a negative cash flow from operations.
LXEO had negative earnings in each of the past 5 years.
LXEO had a negative operating cash flow in each of the past 5 years.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

LXEO has a Return On Assets (-64.85%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -82.60%, LXEO is in line with its industry, outperforming 51.87% of the companies in the same industry.
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for LXEO has been increased compared to 1 year ago.
Compared to 1 year ago, LXEO has an improved debt to assets ratio.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 2.60 indicates that LXEO is not a great score, but indicates only limited risk for bankruptcy at the moment.
LXEO has a Altman-Z score of 2.60. This is in the better half of the industry: LXEO outperforms 66.23% of its industry peers.
LXEO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
LXEO has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.6
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.43 indicates that LXEO has no problem at all paying its short term obligations.
LXEO has a Current ratio (4.43) which is in line with its industry peers.
A Quick Ratio of 4.43 indicates that LXEO has no problem at all paying its short term obligations.
LXEO has a Quick ratio (4.43) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.43
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

LXEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.70%, which is quite impressive.
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LXEO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.51% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.55%
EPS Next 2Y16.25%
EPS Next 3Y11.44%
EPS Next 5Y14.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.25%
EPS Next 3Y11.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (10/9/2025, 7:26:17 PM)

After market: 8.15 -0.05 (-0.61%)

8.2

+0.17 (+2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-13 2025-11-13/bmo
Inst Owners80.84%
Inst Owner Change0%
Ins Owners0.5%
Ins Owner Change0.82%
Market Cap442.80M
Analysts87.14
Price Target17.78 (116.83%)
Short Float %12%
Short Ratio10.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.21%
Min EPS beat(2)-23.91%
Max EPS beat(2)13.49%
EPS beat(4)2
Avg EPS beat(4)-8.43%
Min EPS beat(4)-28.59%
Max EPS beat(4)13.49%
EPS beat(8)4
Avg EPS beat(8)-50.48%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.22%
EPS NY rev (1m)4.23%
EPS NY rev (3m)7.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.2
P/tB 3.2
EV/EBITDA N/A
EPS(TTM)-3.26
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS0
BVpS2.56
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -82.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.43
Altman-Z 2.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.25%
EPS Next Y16.55%
EPS Next 2Y16.25%
EPS Next 3Y11.44%
EPS Next 5Y14.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.8%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-57.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.53%
OCF growth 3YN/A
OCF growth 5YN/A